Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : IncobotulinumtoxinA
Therapeutic Area : Urology
Study Phase : Phase III
Sponsor : Merz Therapeutics
Deal Size : $19.0 million
Deal Type : Partnership
Merz Strengthens Partnership With Start-up Vensica and Invests up to $3 million
Details : This investment follows the strategic license and collaboration agreement signed in 2021 to utilize Merz’s botulinum neurotoxin A (XEOMIN®) for the innovative ultrasound-assisted delivery catheter of Vensica.
Brand Name : Xeomin
Molecule Type : Large molecule
Upfront Cash : Undisclosed
February 07, 2022
Lead Product(s) : IncobotulinumtoxinA
Therapeutic Area : Urology
Highest Development Status : Phase III
Sponsor : Merz Therapeutics
Deal Size : $19.0 million
Deal Type : Partnership
LOOKING FOR A SUPPLIER?